Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.79 |
| ▸ | MAPT | P10636 | 9/20 | 0.79 |
| ▸ | MEN1 | O00255 | 9/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.77 |
| ▸ | HPGD | P15428 | 5/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.77 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273377 | 0.79 | DHODH (0.80) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL19219784 | 0.79 | KDM4E (0.75) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL28575804 | 0.78 | KDM4E (0.74) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL8614842 | 0.77 | DHODH (0.72) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL28914302 | 0.76 | KDM4E (0.80) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL42477 | 0.76 | DHODH (0.81) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL29788461 | 0.76 | DHODH (0.81) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL15506192 | 0.76 | KDM4E (0.67) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL28574876 | 0.76 | MEN1 (0.75) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL2631309 | 0.75 | CA12 (0.71) | KMT2AMAPTMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | claimed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | TP53, BRDT, VHL | KMT2A 3189/4885MAPT 1629/4885MEN1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.